Schrödinger Inc. has paired up with Zai Lab Ltd. to collaborate on an oncology program targeting DNA damage response (DDR) in a deal that could net Schrödinger up to $338 million.

Burning Rock Biotech Ltd. has formed a global strategic partnership with Impact Therapeutics Inc. to develop companion diagnostics for a pipeline of drugs in the field of synthetic lethality.

Hutchmed Ltd. has struck a deal for Epizyme Inc.’s anticancer therapy Tazverik (tazemetostat) that could bring the latter up to $310 million. The agreement gives Hutchmed rights to research, develop, manufacture and commercialize Tazverik in greater China, which covers mainland China, Hong Kong, Macau and Taiwan.

Eli Lilly and Co. has established a multiyear collaboration with Kumquat Biosciences Inc. for the discovery, development and commercialization of new small molecules for stimulating tumor-specific immune responses. Kumquat will receive $70 million up front, including an equity investment, and is eligible for more than $2 billion in potential milestone payments plus royalties on any marketed products.

Minovia Therapeutics Ltd. will collaborate with Astellas Pharma Inc. to research, develop and commercialize cell therapy programs for treating diseases brought on by mitochondrial dysfunction. The candidates will come from Astellas’ genetically engineered, induced pluripotent stem cells. Haifa, Israel-based Minovia will receive $20 million in cash up front.

Peptidream Inc., fresh off expanding a multibillion-dollar research and license agreement with Takeda Pharmaceutical Co. Ltd. earlier this week, has inked a brand new deal with Alnylam Pharmaceuticals Inc. Valued at up to $2.2 billion, including milestones, the new deal is aimed at the discovery and development of peptide-siRNA conjugates for the delivery of therapies to a wide range of cell types and tissues beyond the liver, the central target of Alnylam's marketed products to date.

In a deal that could be worth up to $565 million, Simcere Pharmaceutical Group Ltd. licensed in glutaminyl cyclase inhibitor varoglutamstat (PQ-912) and monoclonal N3pE-antibody PBD-C06, which target the neurotoxic amyloid species N3pE (pGlu-Abeta), from Vivoryon Therapeutics AG to develop and commercialize for Alzheimer’s disease in greater China.

In a deal worth up to $108 million, ophthalmic startup Eluminex Biosciences Ltd. has licensed the global rights to Fibrogen Inc.’s biosynthetic cornea derived from recombinant human collagen (RHC) type III intended to tackle corneal blindness.